DIANTU TOUZI
Diantu Touzi engaged in asset management, investment management and consulting service.
Similar Organizations
Jingde Touzi
Jingde Touzi engaged in asset management, investment management, and consulting service.
Lianfeng Touzi
Lianfeng Touzi engage in investment management and consulting service.
Maolong Tuozi
Maolong Tuozi engage in asset management, investment management and consulting service.
Xinyu Guoxinqu Gaopeng Dashuju Touzi Hehuo Qiye
Xinyu Guoxinqu Gaopeng Dashuju Touzi Hehuo Qiye engaged in asset management, investment management and consulting service.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-01-04 | YILOS | Diantu Touzi investment in Angel Round - YILOS | 3 M CNY |
| 2015-06-08 | Fansheng Tuxiang | Diantu Touzi investment in Series A - Fansheng Tuxiang | 10 M CNY |
More informations about "Diantu Touzi"
Diantu Touzi - Crunchbase Investor Profile & Investments
YILOS raised CN¥3,000,000 / Angel from Diantu Touzi. Discover more funding rounds . Funding Round ...See details»
Diantu Touzi - Investments, Portfolio & Company Exits - Crunchbase
Diantu Touzi engaged in asset management, investment management and consulting service.See details»
YILOS - Crunchbase Company Profile & Funding
Organization. YILOS . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... YILOS is funded by Diantu Touzi. How much …See details»
DIAN-TU Funding and Study Team
Eli Lilly and Company Team. Isabella Velona, Clinical Trial Project Manager; Scott Andersen, Biostatistician; Michele Mancini, GPS; Brian Willis, PK/PD Project LeaderSee details»
The Knight Family DIAN-TU Primary Prevention Trial Announcement
Apr 18, 2024 See all news The Knight Family DIAN-TU Primary Prevention Trial Announcement. May 7, 2024. The statement below is an update to the 20 December 2022 announcement by …See details»
Diantu Touzi — 2 Portfolio companies, 2 Investments, Team
Diantu Touzi. Search. Overview Investments Unlock datapoints. Portfolio analytics Team News & Media. Add fund to favorites. Save this fund for later to form your own custom list of funds. …See details»
Alzheimer’s Drug Discovery Foundation (ADDF) Statement on …
Feb 10, 2020 Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), shares his perspectives on the topline results …See details»
Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU)
A locked padlock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.See details»
The DIAN-TU Next Generation Alzheimer's prevention trial
Introduction: The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's …See details»
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): …
Mar 19, 2024 Background Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future …See details»
The DIAN-TU Next Generation Alzheimer’s prevention trial: …
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer’s disease in …See details»
YILOS - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jan 4, 2018: Angel Round - …See details»
Paper Alert: DIAN-TU Solanezumab and Gantenerumab Data …
25 Jun 2021. Results from the first two arms of the Dominantly Inherited Alzheimer’s Network trials unit (DIAN-TU) are now published. In the June 21 Nature Medicine, researchers led by …See details»
DIAN-TU Tau Next Generation – FULLY FUNDED - Alzheimer's …
A leading Alzheimer's prevention study is breaking new ground by testing three investigational anti-tau drugs in at-risk families, with at least one anti-tau drug to be tested in combination with …See details»
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open
Apr 10, 2020 Lon S. Schneider University of Southern California Keck School of Medicine; Posted: 10 Apr 2020 Despite the null cognitive effects after four years of randomized treatment …See details»
The DIAN‐TU Next Generation Alzheimer's prevention trial: …
Aug 29, 2016 1 Introduction. Alzheimer's disease (AD) is a growing public and financial healthcare crisis. AD afflicts >5 million people in the United States (US), with an expected …See details»
Solanezumab, Gantenerumab Fail to Slow Alzheimer Progression, …
Apr 6, 2020 Howard Fillit, MD. Earlier this year, researchers from Washington University School of Medicine in St. Louis announced negative topline results for the phase 3 Dominantly …See details»
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): …
Background: Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to …See details»
Investigational drugs didn’t slow memory loss, cognitive decline in ...
Feb 10, 2020 WashU Medicine. 660 S. Euclid Ave., St. Louis, MO 63110-1010. WashU Medicine is committed to changing the world by helping improve the human condition through research, …See details»
The DIAN-TU Next Generation Alzheimer's prevention trial: …
Jan 1, 2017 Alzheimer's disease (AD) is a growing public and financial healthcare crisis. AD afflicts >5 million people in the United States (US), with an expected increase to 13.8 million …See details»